Kapetral F.C. Tablets 150mg

AU:D L01BC06(WHO) AU:S4(Prescription only)CA:℞-onlyUK:POM(Prescription only)US:℞-onlyEU:Rx-only Pentyl [1-(3,4-dihydroxy-5-methyltetrahydrofuran-2-yl)-5-fluoro-2-oxo-1H-pyrimidin-4-yl]carbamate 154361-50-9Y 60953 6799 DB01101Y 54916Y 6804DJ8Z9U D01223Y CHEBI:31348Y ChEMBL1773Y DTXSID3046451 Interactive image FC=1\C(=N/C(=O)N(C=1)[C@@H]2O[C@@H]([C@@H](O)[C@H]2O)C)\NC(=O)OCCCCC InChI=1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1YKey:GAGWJHPBXLXJQN-UORFTKCHSA-NY Capecitabine, sold under the brand nameXelodaamong others, is ananticancer medicationused to treatbreast cancer,gastric cancerandcolorectal cancer.For breast cancer it is often used together withdocetaxel.It is takenby mouth. Common side effects include abdominal pain, vomiting,diarrhea, weakness, and rashes.Other severe side effects include blood clotting problems,allergic reactions, heart problems such ascardiomyopathy, andlow blood cell counts.Use duringpregnancymay result in harm to the fetus.Capecitabine, inside the body, is converted to5-fluorouracil(5-FU) through which it acts.It belongs to the class of medications known asfluoropyrimidines, which also includes5-FUandtegafur. Capecitabine was patented in 1992 and approved for medical use in 1998.It is on theWorld Health Organization's List of Essential Medicines.